Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

Charles G. Drake, Russell K. Pachynski, Sumit K. Subudhi, Douglas G. McNeel, Emmanuel S. Antonarakis, Todd M. Bauer, Peter Lauer, Dirk Brockstedt, Daniel Patricia, Mark Wade, Enrique Zudaire, Nibedita Bandyopadhyay, Dolly A. Parasrampuria, Suzette Girgis, Gary E. Mason, Roland E. Knoblauch, Nicole Stone, Jeffrey R. Infante, Marco M. Gottardis, Lawrence Fong

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences